REGENXBIO (NASDAQ:RGNX) Cut to Sell at StockNews.com

StockNews.com downgraded shares of REGENXBIO (NASDAQ:RGNX) from a hold rating to a sell rating in a research report released on Saturday.

A number of other research analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. Raymond James assumed coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Morgan Stanley reiterated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average target price of $33.45.

REGENXBIO Price Performance

Shares of RGNX opened at $7.30 on Friday. The company has a market cap of $361.64 million, a P/E ratio of -1.45 and a beta of 1.29. The stock has a fifty day moving average price of $7.83 and a 200 day moving average price of $9.74. REGENXBIO has a 12 month low of $6.56 and a 12 month high of $28.80.

Institutional Trading of REGENXBIO

Several institutional investors have recently modified their holdings of RGNX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of REGENXBIO by 9.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 6,105 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of REGENXBIO by 164.7% during the fourth quarter. Two Sigma Advisers LP now owns 180,000 shares of the biotechnology company’s stock valued at $1,391,000 after purchasing an additional 112,000 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of REGENXBIO by 209.2% during the fourth quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company’s stock valued at $3,010,000 after purchasing an additional 263,495 shares during the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of REGENXBIO by 22.4% during the fourth quarter. Rafferty Asset Management LLC now owns 93,821 shares of the biotechnology company’s stock valued at $725,000 after purchasing an additional 17,180 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of REGENXBIO during the fourth quarter valued at $447,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.